MDx Company DxNA Buying PCR-based Assay Development Firm PathoGene

Jul 17, 2013

|

NEW YORK (GenomeWeb News) – Molecular diagnostics shop DxNA has signed a letter of intent to acquire PCR-based assay development company PathoGene, the companies said this week.

Terms of the deal were not revealed, but the companies said the acquisition is anticipated to be completed during the next six months, contingent on the completion of due diligence and other conditions.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

A 'Vague' $35 Billion Threat

A new Trump executive order about "free inquiry" on college campuses may threaten $35 billion-worth of federal research funding, reports Ars Technica.

An Expensive Barrier

As we enter conference season, Nature News asks why graduate students and postdocs are sometimes forced to choose between paying the rent and paying to attend important meetings.

A Pushback on Paternal Mitochondrial DNA Inheritance

A new analysis says that a 2018 study claiming to show biparental mtDNA inheritance has several flaws.

This Week in PNAS

In PNAS this week: a genome sequence analysis of Crucihimalaya himalaica, multicellularity and fruiting body development in mushroom-forming fungi, and more.

Featured White Papers

Automated RT qPCR Utilizing the Access Workstation, the Echo Liquid Handler, and RealTime Ready Reagents from Roche Applied Science

High-throughput Miniaturized Quantitative PCR with the Echo 525 Liquid Handler

Miniaturization of the KASP Genotyping Assay for Maize with the Echo 525 Liquid Handler

Mar

27

Featured Webinar

How One NGS Core Lab Reduced Sequencing Costs with a Novel Library Normalization Kit

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.

May

08

Featured Webinar

OncoBEAM ctDNA Testing for Early Response Prediction and Therapy Surveillance in Melanoma and Pancreatic Cancer

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.

May

22

Featured Webinar

A Digital PCR Liquid Biopsy Workflow for Mutation Detection and Therapeutic Monitoring

This webinar will outline the entire liquid biopsy workflow from cell-free DNA isolation to mutation detection by Crystal Digital PCR with the Naica System from Stilla Technologies.

Menu